The regrouping of Luminal B (HER2 negative), a better discriminator of outcome and recurrence score
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5089
Abstract: Breast cancer (BC) remains the leading cause of cancer‐related deaths worldwide. High recurrence risk Luminal BC receives adjuvant chemotherapy in addition to standard hormone therapy. Considering the heterogeneity of Luminal B BC, a more accurate… read more here.
Keywords: regrouping luminal; her2 negative; luminal her2; recurrence ... See more keywords